Biocept Laboratories, which develops and markets cancer diagnostic tests, announced terms for its IPO on Wednesday. The San Diego, CA-based company plans to raise $20 million by offering 1.8 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Biocept Laboratories would command a fully diluted market value of $52 million.
Biocept Laboratories, which was founded in 1997, plans to list on the NASDAQ under the symbol BIOC. Biocept Laboratories initially filed confidentially on August 19, 2013. Aegis Capital is the sole bookrunner on the deal.
